Description: Avita Medical Limited is a medical technology company. The principal activities of the Company are the commercialization of its regenerative product. The Company has three segments: the Asia Pacific region; the Americas, including Canada, and the Europe, Middle East and Africa (EMEA) region. It develops and distributes regenerative products for the treatment of a range of wounds, scars and skin defects. Its collection and application technology provides treatment solutions derived from the regenerative properties of a patient's own skin. The Company's product, ReCell, is used in the treatment of a range of burns, plastic, reconstructive and cosmetic procedures. Its technology, Regenerative Epithelial Suspension (RES), is an autologous suspension composed of the cells and wound-healing factors necessary to regenerate natural skin. The Company also offers ReGenerCell, which is used for the treatment of wounds, and ReNovaCell, which is used for the treatment of pigmentation.
Home Page: www.avitamedical.com
AVH Technical Analysis
28159 Avenue Stanford
Valencia,
CA
91355
United States
Phone:
661 367 9170
Officers
| Name | Title |
|---|---|
| Mr. James M. Corbett | CEO, Pres & Exec. Director |
| Mr. Michael Bria Holder MBA | Chief Financial Officer |
| Ms. Kathy M. McGee | Chief Operating Officer |
| Mr. Andrew Quick | Chief Technology Officer |
| Ms. Donna Shiroma | Gen. Counsel & Sec. |
| Ms. Erin Liberto | Chief Commercial Officer |
| Mr. David Fencil | VP of Global Operations |
| Ms. Debbie Garner | VP of Global Marketing |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8754 |
| Price-to-Sales TTM: | 10.5694 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 116 |